Company Information
Industry 制造业
Company Introduction 深圳市海普瑞药业股份有限公司是一家从事医药生产与销售的企业.其主要产品有普通等级肝素钠原料药、FDA等级肝素钠原料药等.本公司是全球产销规模最大、也是我国唯一同时取得美国FDA认证和欧盟CEP认证的肝素钠原料药生产企业。
Main Business 从事于肝素钠原料药研究、生产及销售。
Legal Representative 李锂
Top Executives
董事长:李锂
董事:张平,李坦,单宇
独立董事:吕川,黄鹏,易铭
Top 5 Shareholder
Shareholder name Nature Holding Date
深圳市乐仁科技有限公司流通A股32.31%30/09/2024
厦门金田土投资合伙企业(有限合伙)流通A股27.81%30/09/2024
HKSCCNOMINEESLIMITEDH股15.00%30/09/2024
厦门水滴石穿投资合伙企业(有限合伙)流通A股3.16%30/09/2024
厦门飞来石投资有限公司流通A股2.75%30/09/2024
Company Secretary 钱风奇
Solicitors 北京市中伦律师事务所
Auditors 深圳南方民和会计师事务所有限责任公司
Tel No 0755-26980311
Fax No 0755-86142889
Website www.hepalink.com
Email stock@hepalink.com
Company Address
Register: 广东省深圳市南山区松坪山郎山路21号
Office: 深圳市南山区松坪山郎山路21号
Listing Date 06/05/2010
Shares Capital
Shares Capital: 1,467,296,204
Total A Share: 1,247,201,704
Listed A Share: 1,247,201,704
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 220,094,500
EPS(RMB)* ¥ -0.534
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 8.119
Market Capitalization(RMB) 12.422B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.